logo
Plus   Neg
Share
Email

Arcadis FY Profit Down 35%; Cuts Dividend - Quick Facts

Dutch engineering and consultancy company Arcadis NV (ARCAY.PK) reported a 35 percent decrease in net income for full year 2016 on lower revenues.

For the year, net income declined to 64.2 million euros from 98.7 million euros last year. Net income per share decreased 36 percent to 0.76 euros from 1.19 euros last year.

Net income from operations was 91.0 million euros, down 34 percent from 137.1 million euros a year ago. Net income from operations per share fell to 1.08 euros from 1.66 euros in the prior year.

Gross revenues declined 3 percent to 3.33 billion euros from 3.42 billion euros, and net revenues decreased 5 percent to 2.47 billion euros last year. Organically, revenue declined 4 percent.

The decrease in net revenue was mainly due to a 37 percent organic decline in Brazil, and lower revenues in North America, Asia and CallisonRTKL.

Arcadis interim CEO Renier Vree said, "I am confident that our actions position us for profitable growth. We will continue to focus on our clients to increase our backlog and revenues, reduce our cost base, improve project management, expand our Global Excellence Centers, while reducing working capital."

Further, Arcadis proposed a dividend of 0.43 euro per share, down from 0.63 euro per share in the prior year.

Arcadis also said that the process to appoint a new CEO is well advanced, and the company is hopeful that it will be able to make an announcement on this topic in the near future.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
An administrative law judge has ruled that Minnesota regulators should approve Enbridge Inc.'s proposal to replace its aging Line 3 crude oil pipeline only if the company follows the existing route and not its preferred route. Enbridge has applied to replace its Line 3 pipeline from Alberta with new pipe along its existing route. In Minnesota, the planned route deviates from the existing route. CLICK HERE to see America's 10 Best-Selling Drugs Despite high drug costs, most of the top-selling drugs saw sales gains in 2017 compared to the prior year. A large number of the best-selling drugs are primarily for the treatment and management of cancer, diabetes, inflammatory disorders, and HIV... Most Americans have access to health care, though costs and services vary from state to state. However, higher costs do not necessarily translate into better results. The U.S. continues to be outperformed by other wealthy nations on several measures like life expectancy, disease burden and health...
Follow RTT